➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Dow
Medtronic
Express Scripts
McKinsey

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)

Docket   Start Trial Date Filed 2016-09-22
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ACTAVIS PHARMA, INC.; AJANTA PHARMA LIMITED; AJANTA PHARMA USA INC.; AMGEN INC.; AMNEAL PHARMACEUTICALS LLC; AMNEAL PHARMACEUTICALS OF NEW YORK LLC; APOTEX CORP.; APOTEX INC.; AUROBINDO PHARMA LTD.; AUROBINDO PHARMA USA INC.; BRECKENRIDGE PHARMACEUTICAL INC.; CADILA HEALTHCARE LTD.; CIPLA LIMITED; CIPLA LTD.; CIPLA USA INC.; CIPLA USA, INC.; DR. REDDYS LABORATORIES, INC.; DR. REDDYS LABORATORIES, LTD.; HETERO LABS LTD.; HETERO LABS LTD. UNIT V; HETERO USA INC.; MICRO LABS LIMITED; MICRO LABS USA, INC.; MYLAN INC.; MYLAN PHARMACEUTICALS INC.; PIRAMAL HEALTHCARE LIMITED; STRIDES PHARMA GLOBAL PTE LIMITED; STRIDES PHARMA INC.; SUN PHARMA GLOBAL FZE; SUN PHARMACEUTICAL INDUSTRIES LTD.; SUN PHARMACEUTICAL INDUSTRIES, INC.; WATSON LABORATORIES, INC.; ZYDUS PHARMACEUTICALS (USA) INC.
Patents 10,183,004; 6,011,068; 6,211,244; 6,316,460; 9,375,405
Attorneys Aaron F. Barkoff; Alan Richard Silverstein; Alejandro Menchaca; Anil H. Patel; Arun John Mohan; Bindu Ann George Palapura; Brian E. Farnan; C. Kyle Musgrove; Caroline L. Marsili; Christopher B. Essig; David A. Bilson; David Ellis Moore; David M. Fry; Deepro R. Mukerjee; Derek S. Neilson; Dominick T. Gattuso; Elizabeth E. Grden; Elizabeth J. Weiskopf; Elizabeth M. Crompton; Gene A. Lang; George C. Lombardi; Gregory C. Bays; Iams J. Travis; Ian Scott; J. Clayton Athey; Jack B. Blumenfeld; Jaimin H. Shah; Jake M. Holdreith; James S. Green; Jared Thomas Green; John C. Phillips , Jr.; John K. Hsu; John W. Bateman; John W. Shaw; Joseph J. Bellew; Joseph James Bellew; Joseph M. Bennett-Paris; Joseph M. Janusz; Joshua H. Lee; Karen Elizabeth Keller; Kaveh Saba; Kelsey J. Thorkelson; Kenneth Laurence Dorsney; Lance A Soderstrom; Marilyn Neiman; Mark S. Schuman; Martin B. Pavane; Mary Matterer; Maryellen Noreika; Michael J. Farnan; Oren D. Langer; Philip Y. Kouyoumdjian; Rajendra A. Chiplunkar; Samuel T. Lockner; Sara E. Bussiere; Stamatios Stamoulis; Stephanie E. O'Byrne; Stephanie M. Roberts; Stephen B. Brauerman; Steven A. Maddox; Tara L. Feld; William D. Hare; Zachary L. Sorman
Firms Bayard, P.A.; Farnan LLP; Heyman Enerio Gattuso & Hirzel LLP; Morris, Nichols, Arsht & Tunnell; Phillips, Goldman, McLaughlin & Hall, P.A.; Prickett, Jones & Elliott, P.A.; Schiff Hardin LLP; Shaw Keller LLP; Stamoulis & Weinblatt LLC; White & Williams
Link to Docket External link to docket
Small Molecule Drugs cited in Amgen Inc. v. Amneal Pharmaceuticals
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Amgen Inc. v. Amneal Pharmaceuticals
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-12-15 14 and/or (c). Amgen also owns U.S. Patent No. 6,011,068, which is listed in the Orange Book listing…undergo parathyroidectomy. U.S. Patent No. 9,375,405 (the “’405 patent”) is listed in Approved Drug Products…‘405 patent invalid. 2. A judgment that no asserted claim of the ‘405 patent is infringed…Substance of the Actions These are Hatch-Waxman patent infringement actions relating to cinacalcet hydrochloride…United States prior to the expiration of the ’405 patent. By letter dated August 5, 2016, Aurobindo notified External link to document
2018-03-23 348 Consent Judgment admitted that Amgen’s United States Patent Number 9,375,405 (the “Amgen Patent”) is enforceable and valid. … Settlement Agreement, would infringe the Amgen Patent. 5. Defendants, including any of its successors…successors and assigns, are enjoined under the ’405 patent, and under any extensions and/or additional periods… or becomes entitled, from infringing the Amgen Patent, on its own part or through any Afflliate, by making…22 September 2016 1:16-cv-00853 830 Patent None District Court, D. Delaware External link to document
2018-04-19 357 Memorandum Opinion Defendants infringed United States Patent No. 9,375,405 (“the ’405 patent”) titled “Rapid Dissolution Formulation… 1. The ’405 Patent The ’405 patent issued from U.S. Patent Application No. 12/942,…OPINION This is a consolidated case for patent infringement brought by Plaintiff Amgen Inc. (…construed the meaning of the Markush groups in the ’405 patent; and (ii) Zydus’ Motion in Limine to preclude …case will be decided based on claim 1 of the ’405 patent, which states: (1) A pharmaceutical External link to document
2018-07-27 375 Opinion accord D.I. 353 at 182:10-183:4). C. Prosecution of the ’405 Patent 1. …consolidated patent infringement action arising under the Drug Price Competition and Patent Term Restoration…Hatch-Waxman Act. United States Patent No. 9,375,405 (the “’405 patent”) is assigned to Plaintiff Amgen…BACKGROUND A. The ’405 Patent The ’405 patent, entitled “Rapid Dissolution Formulation… was issued by the United States Patent and Trademark Office (“Patent Office”) on June 28, 2016. (D.I External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Medtronic
Baxter
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.